The H275Y neuraminidase mutation of the pandemic A/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells, potentially compromising fitness in ferrets

Journal of Virology

Volumn 86, Issue 19, 2012, Pages 10651-10660

  Pinilla, Lady Tatiana ^a   Holder, Benjamin P ^b   Abed, Yacine ^a   Boivin, Guy ^a   Beauchemin, Catherine A A ^b  

^a LAVAL UNIVERSITY   (Canada)

^b RYERSON UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS SIALIDASE;

2009 H1N1 INFLUENZA; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FERRET; FITNESS; GENE MUTATION; IN VITRO STUDY; INFLUENZA VIRUS A H1N1; MALE; MATHEMATICAL MODEL; MIXED INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; FERRETS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; KINETICS; MALE; MODELS, STATISTICAL; MODELS, THEORETICAL; MUTATION; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; REGRESSION ANALYSIS; RNA; VIRUS REPLICATION;

MUSTELA; ORTHOMYXOVIRIDAE;

EID: 84869025419     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.07244-11     Document Type: Article

References (48)

1. Abed Y, Goyette N, Boivin G. 2004. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir. Ther. 9:577-581.
2. Abed Y, Pizzorno A, Bouhy X, Boivin G. 2011. Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses. PLoS Pathog. 7:e1002431. doi:10.1371/journal.ppat.1002431.
3. Baz M, Abed Y, McDonald J, Boivin G. 2006. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin. Infect. Dis. 43:1555-1561.
4. Baz M, et al. 2009. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N. Engl. J. Med. 361:2296.
5. Baz M, Abed Y, Simon P, Hamelin M, Boivin G. 2010. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J. Infect. Dis. 201:740-745.
6. Bloom JD, Gong LI, Baltimore D. 2010. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328: 1272-1275.
7. Bloom JD, Nayak JS, Baltimore D. 2011. A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir- resistant influenza neuraminidase. PLoS One 6:e22201. doi:10.1371/journal.pone.0022201.
8. Bouvier NM, Rahmat S, Pica N. 2012. Enhanced mammalian transmissibility of seasonal influenza A/H1N1 viruses encoding an oseltamivirresistant neuraminidase. J. Virol. 86:7268-7279.
9. Brookes DW, Miah S, Lackenby A, Hartgroves L, Barclay WS. 2011. Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness. J. Antimicrob. Chemother. 66:466-470.
10. Centers for Disease Control and Prevention. 2009. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses. MMWR Morb. Mortal. Wkly. Rep. 58:433-435.
11. Dharan N et al. 2009. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301:1034-1041.
12. Duan S, et al. 2010. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog. 6:e1001022. doi:10.1371/journal.ppat.1001022.
13. Efron B, Tibshirani R. 1986. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat. Sci. 1:77-97.
14. European Centre for Disease Prevention and Control. August2011. Biweekly influenza surveillance overview 26 August 2011. Technical report, European Centre for Disease Prevention and Control. European Centre for Disease Prevention and Control, Stockholm, Sweden. http://ecdc.europa.eu/en/publications/Publications/110826_SUR_Weekly_Influenza_Surveillance_Overview.pdf.
15. Hamelin ME, et al. 2010. Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoS Pathog. 6:e1001015. doi:10.1371/journal.ppat.1001015.
16. Hamelin ME, et al. 2011. Reduced airborne transmission of oseltamivirresistant pandemic A/H1N1 virus in ferrets. Antivir. Ther. 16:775-777.
17. Hatakeyama S, et al. 2005. Enhanced expression of an α-2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J. Clin. Microbiol.43:4139-4146.
18. Hauge S, Dudman S, Borgen K, Lackenby A, Hungnes O. 2009. Oseltamivir- resistant influenza viruses A (H1N1), Norway 2007-2008. Emerg. Infect. Dis. 15:155-162.
19. Hayden FG, de Jong M. 2011. Emerging influenza antiviral resistance threats. J. Infect. Dis. 203:6-10
20. Health Protection Agency. 20 November 2009, posting date. HPA statement on possible transmission of oseltamivir resistant pandemic influenza A(H1N1).Technical report, Government UK. http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1258560561316?p=1231252394302.
21. Herlocher M, et al. 2004. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190:1627-1630.
22. Holder BP, Beauchemin CA. 2011. Exploring the effect of biological delays in kinetic models of influenza within a host or cell culture. BMC Public Health 11:S10. doi:10.1186/1471-2458-11-S1-S10.
23. Holder BP, Liao LE, Simon P, Boivin G, Beauchemin CA. 2011. Design considerations in building in silico equivalents of common experimental influenza virus assays. Autoimmunity 44:282-293.
24. Holder BP, et al. 2011. Assessing fitness of an oseltamivir-resistant seasonal A/H1N1 influenza strain using a mathematical model. PLoS One 6:e14767. doi:10.1371/journal.pone.0014767.
25. Hurt A, et al. 2012. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J. Infect. Dis. 206(2):148-157.
26. Hurt AC, et al. 2012. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect. Dis. 12:240-248.
27. Hurt AC, et al. 2011. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N. Engl. J. Med. 365:2541-2542.
28. Hurt AC, et al. 2010. Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J. Virol. 84:9427-9438.
29. Itoh Y, et al. 2009. In vitro and in vivo characterization of new swineorigin H1N1 influenza viruses. Nature. 460:1021-1025.
30. Ives J, et al. 2002. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leaves virus severely compromised both in vitro and in vivo. Antiviral Res. 55:307-317.
31. Kiso M, et al. 2010. Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. PLoS Pathog. 6:e1001079. doi:10.1371/ journal.ppat.1001079.
32. Lackenby A, et al. 2011. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010-11. Euro Surveill. 16(5):pii19784. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19784.
33. Lakadamyali M, Rust MJ, Babcock HP, Zhuang X. 2003. Visualizing infection of individual influenza viruses. Proc. Natl. Acad. Sci. U. S. A. 100:9280-9285.
34. Le QM, et al. 2010. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N. Engl. J. Med. 362:86-87.
35. Maines TR, et al. 2009. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science. 325:484-487.
36. Marcus PI, Ngunjiri JM, Sekellick MJ. 2009. Dynamics of biologically active subpopulations of influenza virus: plaque-forming, noninfectious cell-killing, and defective interfering particles. J. Virol. 83:8122-8130.
37. Matrosovich MN, Matrosovich T, Gray T, Roberts NA, Klenk HD. 2004. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol. 78:12665-12667.
38. Memoli MJ, et al. 2011. Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. J. Infect. Dis. 203:348-357.
39. Pizzorno A, Bouhy X, Abed Y, Boivin G. 2011. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J. Infect. Dis. 203:25-31.
40. Public Health Agency of Canada. 2011. Fluwatch 2011, weeks 33 and 34.Technical report, Government of Canada. Public Health Agency of Canada, Ottawa, Ontario, Canada. http://www.phac-aspc.gc.ca/fluwatch/10-11/w34_11/index-eng.php.
41. Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S. 2008. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistanc to oseltamivir. PLoS Pathog. 4:e1000103. doi:10.1371/journal.ppat.1000103.
42. Renaud C, Kuypers J, Englund JA. 2011. Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1. J. Clin. Virol. 52:70-78.
43. Reuman PD, Keely S, Schiff GM, Gamble JN. 1989. Assessment of signs of influenza illness in the ferret model. J. Virol. Methods 24:27-34.
44. Rust MJ, Lakadamyali M, Zhang F, Zhuang X. 2004. Assembly of endocytic machinery around individual influenza viruses during viral entry. Nat. Struct. Mol. Biol. 11:567-573.
45. Seibert CW, et al. 2010. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J. Virol. 84:11219-11226.
46. Seibert CW, Rahmat S, Krammer F, Palese P, Bouvier NM. 2012. Efficient transmission of pandemic H1N1 influenza viruses with highlevel oseltamivir resistance. J. Virol. 86:5386-5389.
47. Storms A, et al. 2012. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg. Infect. Dis. 18:308-311.
48. van der Vries E, et al. 2010. Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase. J. Clin.Virol. 47:34-37